Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 15/20 | 0.77 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.77 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.77 |
| ▸ | CCR2 | P41597 | 1/20 | 0.77 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.77 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL209072 | 0.98 | CXCR4 (0.78) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| SCHEMBL211040 | 0.93 | SIGMAR1 (0.66) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| SCHEMBL11342016 | 0.93 | SIGMAR1 (0.66) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL3062972 | 0.91 | CXCR4 (0.66) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL6291076 | 0.91 | CXCR4 (0.66) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| SCHEMBL13250512 | 0.89 | CXCR4 (0.70) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| SCHEMBL29490414 | 0.87 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| SCHEMBL5611617 | 0.87 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| Plerixafor SCHEMBL19038 | 0.87 | CXCR4 (1.00) | CXCR4HRH3MEN1CHRM2CHRM1 | |
| SCHEMBL12203046 | 0.86 | CXCR4 (0.77) | CXCR4HRH3MEN1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382301-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | UNIV ARIZONA (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4543888-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | Arizona Board of Regents on behalf of The University of Arizona (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2023250083-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-12-28 | — | — | WO | disclosed |
| US-20150141429-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI INC. (US) | 2015-05-21 | — | — | US | disclosed |
| EP-2842956-A1 | PARP inhibitor compounds, compositions and methods of use | Eisai Inc. (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8894989-B2 | PARP inhibitor compounds, compositions and methods of use | EISAI INC. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-1963315-B1 | ENZYME INHIBITORS | CANCER REC TECH LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20130011365-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EISAI INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8236802-B2 | PARP inhibitor compounds, compositions and methods of use | EISAI INC. (US) | 2012-08-07 | — | — | US | disclosed |
| EP-1673092-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA Bioscience nv (BE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005039587-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA BIOSCIENCE NV (BE) | 2005-05-06 | — | — | WO | disclosed |
| EP-0252670-B1 | 2-SUBSTITUTED ALKOXY-3-SUBSTITUTED-PYRAZINES | TOYO JOZO KABUSHIKI KAISHA (JP) | 1992-01-15 | — | — | EP | disclosed |
| US-5001237-A | 2-substituted alkoxy-3-substituted-pyrazines | TOYO JOZO KABUSHIKI KAISHA (JP) | 1991-03-19 | — | — | US | disclosed |
| EP-0242957-B1 | 1-SUBSTITUTED ALKYL-1, 2-DIHYDRO-2-PYRAZINONE DERIVATIVES | TOYO JOZO KABUSHIKI KAISHA (JP) | 1990-09-12 | — | — | EP | disclosed |
| US-4894453-A | ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1990-01-16 | — | — | US | disclosed |
| US-4877875-A | ANTIAGGLOMERANTS, VASODILATORS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1989-10-31 | — | — | US | disclosed |
| US-4837319-A | VASODILATORS, ANTICOAGULANTS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1989-06-06 | — | — | US | disclosed |
| EP-0252670-A2 | 2-Substituted alkoxy-3-substituted-pyrazines | TOYO JOZO KABUSHIKI KAISHA (JP) | 1988-01-13 | — | — | EP | disclosed |
| EP-0242957-A1 | 1-Substituted Alkyl-1, 2-Dihydro-2-Pyrazinone derivatives | TOYO JOZO KABUSHIKI KAISHA (JP) | 1987-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141429-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PARP1, PARP3, PARP2 | CXCR4 3463/4885HRH3 2708/4885MEN1 1486/4885 |
| US-20130011365-A1 | PARP INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PARP1, PARP3, PARP2 | CXCR4 3569/4885HRH3 2316/4885MEN1 1470/4885 |
| US-20250382301-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK3, CLK1 | CXCR4 590/4885HRH3 348/4885MEN1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.